|
Jul 26
|
Roche records 4% decline in H1 2024 net income
|
|
Jul 25
|
Why Weight Loss Drug Developer Stocks Tumbled on Thursday
|
|
Jul 25
|
Health Care Roundup: Market Talk
|
|
Jul 25
|
AstraZeneca Says It Has A 'Powerful' — And Differentiated — Approach To Obesity Treatment
|
|
Jul 25
|
Roche (RHHBY) Sales, Earnings Grow in 1H24, '24 EPS View Raised
|
|
Jul 25
|
Roche says it’ll move quickly with ‘differentiated’ obesity drugs
|
|
Jul 25
|
[Ad hoc announcement pursuant to Art. 53 LR] Roche sales increase by 5% (CER) in first half of 2024; strong growth in second quarter – full-year earnings outlook raised
|
|
Jul 23
|
Look Out, Eli Lilly and Novo Nordisk: Could Roche Be the Obesity Drug Stock to Really Watch?
|
|
Jul 22
|
ETFs in Focus as Competition Heats Up in Weight Loss Drug Segment
|
|
Jul 22
|
This Big Pharma Could Become a Leading Weight-Loss Stock. Should You Buy It?
|
|
Jul 22
|
The Zacks Analyst Blog Highlights Broadcom, Roche, Micron Technology and Moving iMage Technologies
|
|
Jul 22
|
Better Dark Horse Weight Loss Drug Stock: Pfizer vs. Roche
|
|
Jul 21
|
How a single daily pill could soon be the future of losing weight
|
|
Jul 9
|
Roche relaunches refillable wet AMD implant two years after recall
|
|
Jul 9
|
Roche’s AI-enabled continuous glucose monitoring solution receives CE Mark
|
|
Jul 9
|
Roche receives CE Mark for its AI-enabled continuous glucose monitoring solution offering critical predictions to people living with diabetes
|
|
Jul 8
|
Here's Why Sarepta (SRPT) Stock Price Surged 57% YTD
|
|
Jul 8
|
Roche to reintroduce Susvimo in the US for people with neovascular age-related macular degeneration (nAMD)
|
|
Jul 8
|
Ligand to buy Apeiron; Roche reports another TIGIT setback
|
|
Jul 8
|
The Zacks Analyst Blog Highlights Eli Lilly, Sanofi Merck, AstraZeneca's and Roche
|